KUNIZ 28 DAYS STARTER PACK (APREMILAST) 10mg 20mg 30mg TABLETS

KUNIZ 28 DAYS STARTER PACK (APREMILAST) 10mg 20mg 30mg TABLETS: A Comprehensive Overview

Modern medicine continues to advance in treating various diseases and conditions. One such medical marvel is Kuniz, a medication in tablet form containing Apremilast, which has
shown immense promise in addressing certain autoimmune disorders. In this comprehensive article, we will delve into the composition, description, indications, usage, dosage, clinical pharmacology, and much more surrounding Kuniz tablets

Composition:

Kuniz tablets come in different strengths, each tailored to specific medical needs:

• Kuniz 10mg Tablets: Each filmcoated tablet contains 10mg of Apremilast
• Kuniz 20mg Tablets: For more robust requirements, these tablets contain 20mg of Apremilast
• Specific cases warrant the prescription of Kuniz 30mg Tablets, which contain the highest strength of 30mg Apremilast.

The active ingredient, Apremilast, is a phosphodiesterase 4 (PDE4) Inhibitor. Its chemical name is N(2-(4-ethoxy-3-methoxyphenyl)-1-(methylsulfonyl)ethyl)-2,3-dioxo-1,3-dihydro-1H-isoindol-4-yl acetamide, characterized by an empirical formula of C22H24N2O7S and a molecular weight of 460.5.

Indications and Usage:

Kuniz tablets have been approved for several medical
conditions:

• Kuniz offers hope and relief to adult patients with active psoriatic arthritis, treating this autoimmune joint disorder.
• Recommend it for the treatment of patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic therapy
• Kuniz can provide much-needed relief from the painful condition of oral ulcers associated with Behcet’s disease when treating adult patients.

Dosage and Administration:

The dosage of Kuniz tablets varies depending on the medical
condition being treated. Here are the recommended initial dosages and titration schedules for Psoriatic Arthritis and Psoriasis:

•  Initial titration from Day 1 to Day 5, starting with 10mg, then 20mg, and eventually reaching 30mg twice daily from Day 6 onward
• When administering Apremilast tablets, ensure they remain intact and avoid crushing, splitting, or chewing them. These tablets can be taken irrespective of meals.
• Patients with severe renal impairment (creatinine clearance less than 30 mL per minute) should take a reduced dosage of 30mg once daily.

Clinical Pharmacology:

Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), is responsible for Kuniz’s mechanism of action. At present, there isn’t a complete understanding of how Apremilast precisely achieves its therapeutic effects in psoriatic arthritis and psoriasis.

In terms of pharmacokinetics, Apremilast exhibits good oral absorption with a bioavailability of approximately 73%. Peak plasma concentrations occur at a median time of around 2.5 hours, and co-administration with food does not affect its absorption. During the extensive metabolism of Apremilast in humans, researchers have identified several metabolites in plasma, urine, and feces.

The plasma clearance of Apremilast is about 10 L/hr, and it has a terminal elimination half-life of approximately 69 hours. Urine and feces excrete a significant portion of the drug.

Conclusion:

In conclusion, Kuniz tablets containing Apremilast offer hope and relief to patients battling psoriatic arthritis, psoriasis, and oral ulcers associated with Behcet’s disease. The medication’s well-defined dosage and clinical pharmacology make it a valuable addition to the arsenal of
treatments available to healthcare professionals in their quest to improve the lives of those affected by these autoimmune conditions. As medical science continues to progress, we can anticipate even more breakthroughs in the treatment of such disorders, offering a brighter future for patients worldwide